CAR-T– tag –
-
Cell Therapy Weekly: uniQure Plans BLA Submission for Huntington’s Gene Therapy AMT-130; Ernexa Prepares IND for iMSC, Autolus Reports Early Phase I Data for SLE CAR-T
Cell & Gene Therapy Insights USA Overview uniQure plans to submit a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington's disease, in Q3 2026, based on three-year Phase I/II data. Ernexa Therapeutics has comple... -
Pharmaceutical and Biotech M&A Surges in 2026, Driven by Pipeline Reinforcement and Expansion into Emerging Therapeutic Areas
DistilINFO Publications USA Overview The pharmaceutical and biotechnology sectors are experiencing a significant surge in M&A activity in 2026, as major drugmakers actively seek to fortify their pipelines and expand into novel therap... -
CCRM, OmniaBio, and Avectas Collaborate to Automate and Scale Cell Therapy Manufacturing
PR Newswire Canada Overview CCRM and its CDMO subsidiary OmniaBio Inc. have partnered with Avectas Limited to evaluate and integrate Avectas' automated, scalable cell therapy manufacturing platform. This collaboration aims to enhance con... -
Top Cell Therapy Startups Secure Significant Funding for Commercialization, Infrastructure, and Novel Modalities
New Market Pitch USA Overview Leading cell therapy startups are attracting substantial investment, indicating investor confidence in high-risk technical innovation. Companies like Orca (near-commercial assets), Cellares (manufacturing in... -
Autolus Therapeutics Wins Prix Galien UK for Best Biotech Product, Reports Promising Early Phase 1 Data for obe-cel CAR-T in Refractory SLE
Stock Titan UK Overview Autolus Therapeutics plc received the 2026 Prix Galien UK Award for Best Biotechnology Product, recognizing its pioneering work in next-generation T-cell therapies developed with University College London. Concurr... -
FDA Grants RMAT Designation to Cellectis’ Allogeneic CD22 CAR-T Lasme-cel for Relapsed/Refractory B-ALL
Targeted Oncology USA Overview The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Cellectis' lasmecabtagene timgedleucel (lasme-cel; UCART22), an allogeneic CD22-targeting CAR-T cell therapy, for relapsed/re... -
Preprint Reviews NKG2D CAR-NK Cell Progress in Cancer Immunotherapy: Low GVHD Risk, Scalable Manufacturing, and iPSC-Derived NK Cells as a Platform for Off-the-Shelf Therapies
Preprints.org International Overview A preprint on Preprints.org reviews recent progress in NKG2D CAR-NK cells for cancer immunotherapy, highlighting their favorable safety profile with rare instances of graft-versus-host disease (GVHD) ... -
Cartesian Therapeutics and WestGene Biopharma Announce Strategic Licensing Agreement to Accelerate In Vivo CAR T Platform Development for Autoimmune Diseases
BioSpace (Cartesian Therapeutics) USA Overview Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to accelerate the development of novel in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies for... -
Terumo Unveils ‘Ecosystem Blueprint’ to Scale Cell Therapies in Asia, Integrating Workflow, Equipment, and Training
Regen Report Japan Overview Terumo has introduced a new 'Ecosystem Blueprint' aimed at supporting the scaling of cell therapies in the Asia-Pacific region. This strategy seeks to transition cell therapies from early development to scalab... -
ENCell Secures US Clinical Manufacturing Contract for Ingenium’s AML-Targeting NK Cell Therapy, ‘gengleucel’
KBR South Korea Overview ENCell, a CDMO specializing in cell and gene therapies, has secured a manufacturing contract for Ingenium Therapeutics' allogeneic NK cell therapy candidate, 'gengleucel,' for U.S. clinical trials. This therapy t...
